Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome

Pavelek,Zbyšek; Vyšata,Oldřich; Tambor,Vojtěch; Pimková,Kristýna; Vu,Dai  Long; Kuča,Kamil; Šťourač,Pavel; Vališ,Martin

doi:10.3892/br.2016.668

Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome

Authors:
- Zbyšek Pavelek
- Oldřich Vyšata
- Vojtěch Tambor
- Kristýna Pimková
- Dai Long Vu
- Kamil Kuča
- Pavel Šťourač
- Martin Vališ
View Affiliations

Affiliations: Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, CZ-500 05 Hradec Králové, Czech Republic, Biomedical Research Center, University Hospital Hradec Králové, CZ-500 05 Hradec Králové, Czech Republic, Department of Neurology, Faculty of Medicine and University Hospital Brno, CZ-639 00 Brno, Czech Republic
Published online on: April 28, 2016 https://doi.org/10.3892/br.2016.668
Pages: 35-40
Copyright: © Pavelek et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Early diagnosis and treatment of multiple sclerosis (MS) in the initial stages of the disease can significantly retard its progression. The aim of the present study was to identify changes in the cerebrospinal fluid proteome in patients with relapsing-remitting MS and clinically isolated MS syndrome who are at high risk of developing MS (case group) compared to healthy population (control) in order to identify potential new markers, which could ultimately aid in early diagnosis of MS. The protein concentrations of each of the 11 case and 15 control samples were determined using a bicinchoninic acid assay. Nanoscale liquid chromatography coupled with tandem mass spectrometry was used for protein identification. Proteomics data were processed using the Perseus software suite and R. The results were filtered using the Benjamini‑Hochberg procedure for the false discovery rate (FDR) correction (FDR<0.05). The results showed that, 26 proteins were significantly dysregulated in case samples compared to the controls. Nine proteins were found to be significantly less abundant in case samples, while the abundance of 17 proteins was significantly increased in case samples compared to controls. Three of the proteins were previously linked to RR MS, including immunoglobulin (Ig) γ-1 chain C region, Ig heavy chain V-III region BRO and Ig κ chain C region. Three proteins that were uniquely expressed in patients with RR MS were identified and these proteins may serve as prognostic biomarkers for identifying patients with a high risk of developing RR MS.

View Figures

View References

1.	Krejsek J: News in the pathogenesis of multiple sclerosis. What is hidden behind the disability of MS patients. Remedia. 2014:S2–S4. 2014.(In Czech).
2.	Cree B and Vollmer TL: Clinically isolated syndrome: Evaluation, risk stratification, and treatment decisions. Adv Stud Med. 8:257–265. 2008.
3.	Garcea O, Villa A, Cáceres F, Adoni T, Alegría M, Barbosa Thomaz R, Buzo R, Llamas López L and Rivera Kindel M: Early treatment of multiple sclerosis: A Latin American experts meeting. Mult Scler. 15(Suppl 3): S1–S12. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW and Willmon TL: Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 122:552–568. 1965. View Article : Google Scholar : PubMed/NCBI
5.	Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH and Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 13:227–231. 1983. View Article : Google Scholar : PubMed/NCBI
6.	McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 50:121–127. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol. 58:840–846. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 69:292–302. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Tintoré M: Rationale for early intervention with immunomodulatory treatments. J Neurol. 255(Suppl 1): 37–43. 2008. View Article : Google Scholar
10.	Miller JR: The importace of early diagnosis of multiple sclerosis. J Manag Care Pharm. 10:S4–S11. 2004.PubMed/NCBI
11.	Kroksveen AC, Guldbrandsen A, Vedeler C, Myhr KM, Opsahl JA and Berven FS: Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl. 195:90–96. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ and Berven FS: Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics. 74:371–388. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, et al: Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 73:1117–1132. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Kroksveen AC, Aasebø E, Vethe H, Van Pesch V, Franciotta D, Teunissen CE, Ulvik RJ, Vedeler C, Myhr KM, Barsnes H, et al: Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J Proteomics. 78:312–325. 2013. View Article : Google Scholar : PubMed/NCBI
15.	Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E, Alvarez-Cermeño JC, et al: Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 133:1082–1093. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Stoop MP, Singh V, Dekker LJ, Titulaer MK, Stingl C, Burgers PC, Sillevis Smitt PA, Hintzen RQ and Luider TM: Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One. 5:e124422010. View Article : Google Scholar : PubMed/NCBI
17.	Cox J and Mann M: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 26:1367–1372. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV and Mann M: Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 10:1794–1805. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Cox J, Hein MY, Luber CA, Paron I, Nagaraj N and Mann M: Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 13:2513–2526. 2014. View Article : Google Scholar : PubMed/NCBI
20.	Gautier L, Cope L, Bolstad BM and Irizarry RA: affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J and Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30:e152002. View Article : Google Scholar : PubMed/NCBI
22.	Christin C, Hoefsloot HC, Smilde AK, Hoekman B, Suits F, Bischoff R and Horvatovich P: A critical assessment of feature selection methods for biomarker discovery in clinical proteomics. Mol Cell Proteomics. 12:263–276. 2013. View Article : Google Scholar : PubMed/NCBI
23.	Clough T, Thaminy S, Ragg S, Aebersold R and Vitek O: Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs. BMC Bioinformatics. 13(Suppl 16): S62012. View Article : Google Scholar : PubMed/NCBI
24.	Lipsy RJ, Schapiro RT and Prostko CR: Current and future directions in MS management: key considerations for managed care pharmacists. J Manag Care Pharm. 15(Suppl A): S2–S15; quiz S16–S17. 2009.PubMed/NCBI
25.	Mareš J: Early treatment of multiple sclerosis - treatment of clinically isolated syndrome, conditions of early diagnosis and treatment of multiple sclerosis. Remedia. 2011.S5–S6, (In Czech).
26.	Tintoré M, Rovira A, Río J, Nos C, Grivé E, Téllez N, Pelayo R, Comabella M, Sastre-Garriga J and Montalban X: Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 67:968–972. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ and Miller DH: Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 131:808–817. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A, Castilló J, et al: Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 19:1878–1886. 2013. View Article : Google Scholar : PubMed/NCBI
29.	Sastre-Garriga J, Tintoré M, Rovira A, Grivé E, Pericot I, Comabella M, Thompson AJ and Montalban X: Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler. 9:39–43. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ, Ketelslegers IA, Peeters E, et al: Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology. 71:967–973. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C, Téllez N, Perkal H, Comabella M, Sastre-Garriga J, et al: Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 70:1079–1083. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Ingram G, Loveless S, Howell OW, Hakobyan S, Dancey B, Harris CL, Robertson NP, Neal JW and Morgan BP: Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun. 2:532014. View Article : Google Scholar : PubMed/NCBI
33.	Ekdahl NK, Blomberg C, Henningsson JA, Dahle C, Håkanssone I, Sandholm K and Ernerudh J: Systemic and intrathecal complement activation in multiple sclerosis and Guillan-Barré syndrome. Mol Immunol. 46:28482009. View Article : Google Scholar
34.	Ingram G, Hakobyan S, Robertson NP and Morgan BP: Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol. 155:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
35.	Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, et al: Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler. 21:1251–1261. 2015. View Article : Google Scholar : PubMed/NCBI
36.	Greenstein J and Cunningham T: Neuroprotective, anti-inflammatory and immune Tolerizing properties of peptides derived from diffusion survival Evasion protein (DSEP)/Dermcidin. Neurology. 82:P1.1752014.